ArticleCytometry. Part B, Clinical cytometry
Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.
Article in Cytometry. Part B, Clinical cytometry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Dimensionality reduction enables MRD visualization in single-sample flow cytometric analysis in acute leukemia.International journal of hematology · 2026Article
- MRD assessment by flow cytometry in B-ALL made easier.Blood advances · 2026Article
- Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.Blood advances · 2026Article
- Review
- The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2024Review
- Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.Cytometry. Part B, Clinical cytometry · 2023Article
- Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.Current protocols · 2022Article
- A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2022Article
- 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.Cytometry. Part B, Clinical cytometry · 2021Article
- Specific Immune Response and Cytokine Production in CD70 Deficiency.Frontiers in pediatrics · 2021Article
- Review
- Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets.Nature communications · 2019Article
- PhenoGraph and viSNE facilitate the identification of abnormal T-cell populations in routine clinical flow cytometric data.Cytometry. Part B, Clinical cytometry · 2018Article
- Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2018Review
- Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.Journal for immunotherapy of cancer · 2017Article
- Sensitive detection of rare disease-associated cell subsets via representation learning.Nature communications · 2017Article
- Functional Virtual Flow Cytometry: A Visual Analytic Approach for Characterizing Single-Cell Gene Expression Patterns.BioMed research international · 2017Article
- Flow cytometry combined with viSNE for the analysis of microbial biofilms and detection of microplastics.Nature communications · 2016Article
- Single-Cell Analysis in Cancer Genomics.Trends in genetics : TIG · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMinimal residual disease (MRD) following treatment is a robust prognostic marker in B lymphoblastic leukemia. However, the detection of MRD by flow cytometric immunophenotyping is technically challenging, and an automated method to detect MRD is therefore desirable. viSNE, a recently developed computational tool based on the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm, has been shown to be capable of detecting synthetic "MRD-like" populations of leukemic cells created in vitro, but whether viSNE can facilitate the immunophenotypic detection of MRD in clinical samples has not been evaluated.
methodsWe applied viSNE retrospectively to 8-color flow cytometric immunophenotyping data from normal bone marrow samples, and samples from B lymphoblastic leukemia patients with or without suspected MRD on the basis of conventional manual gating.
resultsIn each of 14 bone marrow specimens containing MRD or suspected MRD, viSNE identified a putative MRD population; an abnormal composite immunophenotype was confirmed for the putative MRD in each case. MRD populations were not identified by viSNE in control bone marrow samples from patients with increased normal B-cell precursors, or in post-treatment samples from B lymphoblastic leukemia patients who did not have detectable MRD by manual gating.
conclusionviSNE shows promise as an automated method to facilitate immunophenotypic MRD detection in patients treated for B lymphoblastic leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.